-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|November 5, 2024

Improving Access and Equity in VMS Treatment

Author(s)Ryan Haumschild, PharmD, MS, MBA, CPEL, JoAnn V. Pinkerton, MD, FACOG, MSCP , Alexa N. Fiffick, DO, MBS, MSCP

Key Takeaways

Enhancing education for patients and healthcare providers can improve recognition and management of vasomotor symptoms associated with menopause.
Socioeconomic disparities significantly impact access to healthcare resources, influencing the management of vasomotor symptoms.
Initiatives should focus on increasing accessibility to care, providing affordable treatment options, and implementing community outreach programs to bridge gaps in menopause care.

SHOW MORE

Panelists discuss how to improve treatment rates for vasomotor symptoms (VMS) by identifying actionable steps, examining the influence of socioeconomic status on health care access, and proposing initiatives to ensure equitable care for all women experiencing menopause.

Episodes in this series

EP. 1 Understanding the Burden of Menopausal Vasomotor Symptoms

EP. 1 Understanding the Burden of Menopausal Vasomotor Symptoms

EP. 2 Barriers to VMS Treatment and Impact on Long-Term Health

EP. 2 Barriers to VMS Treatment and Impact on Long-Term Health

EP. 3 Improving Access and Equity in VMS Treatment

EP. 3 Improving Access and Equity in VMS Treatment

EP. 4 Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP. 4 Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP. 5 Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP. 5 Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP. 6 Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP. 6 Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP. 7 Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP. 7 Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP. 8 Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP. 8 Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP. 9 Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP. 9 Beyond Hot Flashes: The Importance of Sleep in Menopause Management

EP. 10 Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

EP. 10 Closing Thoughts: Evolving Treatment Paradigms in Menopause Management

Video content above is prompted by the following:

(FIFFICK) What steps can be taken to improve treatment rates of VMS associated with menopause?
(SMITH) How does the intersection of socioeconomic status and access to health care resources influence the management of VMS?
(PINKERTON) What initiatives could help bridge these gaps and ensure more equitable care for all women experiencing menopause?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

FDA Panel Backs 6 Peptides for Compounding

Philadelphia Employer Coalition Podcast Targets GLP-1s, Cancer Care

Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD